methyl 3-(4-((4-chloro-2-methylphenyl)ethynyl)phenyl)-propanoate | 1420837-14-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-(4-((4-chloro-2-methylphenyl)ethynyl)phenyl)-propanoate
• 英文别名: Methyl 3-[4-[2-(4-chloro-2-methylphenyl)ethynyl]phenyl]propanoate；methyl 3-[4-[2-(4-chloro-2-methylphenyl)ethynyl]phenyl]propanoate
• CAS: 1420837-14-4
• 化学式: C₁₉H₁₇ClO₂
• 分子量: 312.796
• InChiKey: UNRYUKHWBJQCCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 3-(4-((4-chloro-2-methylphenyl)ethynyl)phenyl)-propanoate 在 lithium hydroxide monohydrate 、 水 作用下， 以 四氢呋喃 为溶剂， 以99%的产率得到3-[4-[2-(4-Chloro-2-methylphenyl)ethynyl]phenyl]propanoic acid
  参考文献：
  名称：

  Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability

  摘要：

  The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.

  DOI：

  10.1021/jm301470a
• 作为产物：
  描述：

  3-(4-乙炔基苯基)丙酸甲酯 、 2-溴-5-氯甲苯 在 copper(l) iodide 、 sodium tetrachloropalladate(II) 、 四甲基乙二胺 、 2-二叔丁基膦-1-苯基吲哚 作用下， 以 水 为溶剂， 以83%的产率得到methyl 3-(4-((4-chloro-2-methylphenyl)ethynyl)phenyl)-propanoate
  参考文献：
  名称：

  Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability

  摘要：

  The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.

  DOI：

  10.1021/jm301470a

文献信息

• Discovery of a Potent and Selective Free Fatty Acid Receptor 1 Agonist with Low Lipophilicity and High Oral Bioavailability
  作者：Elisabeth Christiansen、Maria E. Due-Hansen、Christian Urban、Manuel Grundmann、Johannes Schmidt、Steffen V. F. Hansen、Brian D. Hudson、Mohamed Zaibi、Stine B. Markussen、Ellen Hagesaether、Graeme Milligan、Michael A. Cawthorne、Evi Kostenis、Matthias U. Kassack、Trond Ulven

  DOI：10.1021/jm301470a

  日期：2013.2.14

  The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.